Advances and applications of engineered protein therapeutics and their role in precision medicine.

IF 5.8 3区 工程技术 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Frontiers in Bioengineering and Biotechnology Pub Date : 2026-10-05 eCollection Date: 2026-01-01 DOI:10.3389/fbioe.2026.1857362
Wadha Aldossary, Nada Alqahtani, Layla Asiri, Noora Alkhurayef, Samar Alagl, Sana Alturki, Duha Saad, Mashael Al Yahya, Samah Al-Harthi
{"title":"Advances and applications of engineered protein therapeutics and their role in precision medicine.","authors":"Wadha Aldossary, Nada Alqahtani, Layla Asiri, Noora Alkhurayef, Samar Alagl, Sana Alturki, Duha Saad, Mashael Al Yahya, Samah Al-Harthi","doi":"10.3389/fbioe.2026.1857362","DOIUrl":null,"url":null,"abstract":"<p><p>Proteins are a vital class of biomolecules. They play essential roles in biological processes, including building cellular structures, forming cellular channels and receptors, catalyzing biological reactions, transporting molecules, and contributing to immune defense mechanisms. Advances in protein engineering have enabled the genetic modification of naturally occurring proteins, using recombinant deoxyribonucleic acid (DNA) technology, leading to the development of therapeutic proteins with enhanced specificity, stability, and clinical performance. Despite the rapid growth of engineered biologics, a comprehensive understanding of how these innovations intersect with precision medicine remains limited. This review addresses this gap by summarizing the major contemporary approaches used in therapeutic protein engineering, including directed evolution, rational design, and <i>de novo</i> protein design, and by analyzing their roles in enabling patient-tailored interventions. It provides an integrated overview of the clinical applications of engineered therapeutic proteins across key medical fields, supported by a list of U.S. Food and Drug Administration- and European Medicines Agency-approved protein therapeutics from 2020 to 2025. The review further provides a comparative perspective on major protein engineering strategies, highlighting their relative advantages and limitations, while examining differences in clinical translation across major disease areas. By combining technological advances with disease-specific applications, this review offers a perspective that has not been fully developed in the literature. Finally, the review discusses the current challenges affecting the implementation of precision medicine, including immunogenicity, regulatory constraints, and ethical considerations, and outlines future directions, such as artificial intelligence-guided protein design, targeted protein degradation, and personalized vaccine development. Collectively, these insights highlight the expanding role of engineered proteins in shaping the next-generation of precision therapeutics and emphasize the growing importance of integrating multidisciplinary approaches to advance therapeutic innovation in modern clinical practice.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"14 ","pages":"1857362"},"PeriodicalIF":5.8000,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13678489/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2026.1857362","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Proteins are a vital class of biomolecules. They play essential roles in biological processes, including building cellular structures, forming cellular channels and receptors, catalyzing biological reactions, transporting molecules, and contributing to immune defense mechanisms. Advances in protein engineering have enabled the genetic modification of naturally occurring proteins, using recombinant deoxyribonucleic acid (DNA) technology, leading to the development of therapeutic proteins with enhanced specificity, stability, and clinical performance. Despite the rapid growth of engineered biologics, a comprehensive understanding of how these innovations intersect with precision medicine remains limited. This review addresses this gap by summarizing the major contemporary approaches used in therapeutic protein engineering, including directed evolution, rational design, and de novo protein design, and by analyzing their roles in enabling patient-tailored interventions. It provides an integrated overview of the clinical applications of engineered therapeutic proteins across key medical fields, supported by a list of U.S. Food and Drug Administration- and European Medicines Agency-approved protein therapeutics from 2020 to 2025. The review further provides a comparative perspective on major protein engineering strategies, highlighting their relative advantages and limitations, while examining differences in clinical translation across major disease areas. By combining technological advances with disease-specific applications, this review offers a perspective that has not been fully developed in the literature. Finally, the review discusses the current challenges affecting the implementation of precision medicine, including immunogenicity, regulatory constraints, and ethical considerations, and outlines future directions, such as artificial intelligence-guided protein design, targeted protein degradation, and personalized vaccine development. Collectively, these insights highlight the expanding role of engineered proteins in shaping the next-generation of precision therapeutics and emphasize the growing importance of integrating multidisciplinary approaches to advance therapeutic innovation in modern clinical practice.

工程蛋白疗法的进展和应用及其在精准医学中的作用。
蛋白质是一类重要的生物分子。它们在构建细胞结构、形成细胞通道和受体、催化生物反应、转运分子以及参与免疫防御机制等生物过程中发挥着重要作用。蛋白质工程的进步使得利用重组脱氧核糖核酸(DNA)技术对天然存在的蛋白质进行遗传修饰成为可能,从而开发出具有更高特异性、稳定性和临床性能的治疗性蛋白质。尽管工程生物制剂发展迅速,但对这些创新如何与精准医学交叉的全面理解仍然有限。本综述通过总结治疗性蛋白质工程中使用的主要当代方法,包括定向进化、理性设计和从头蛋白质设计,并分析它们在实现患者定制干预方面的作用,解决了这一差距。它提供了工程治疗蛋白在关键医学领域的临床应用的综合概述,由美国食品和药物管理局和欧洲药品管理局批准的2020年至2025年蛋白质疗法清单提供支持。该综述进一步提供了主要蛋白质工程策略的比较视角,突出了它们的相对优势和局限性,同时检查了主要疾病领域临床翻译的差异。通过将技术进步与疾病特异性应用相结合,本综述提供了一个尚未在文献中充分发展的观点。最后,综述讨论了当前影响精准医学实施的挑战,包括免疫原性、监管限制和伦理考虑,并概述了未来的方向,如人工智能引导的蛋白质设计、靶向蛋白质降解和个性化疫苗开发。总的来说,这些见解强调了工程蛋白在塑造下一代精确治疗方面的作用日益扩大,并强调了整合多学科方法在现代临床实践中推进治疗创新的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Frontiers in Bioengineering and Biotechnology
Frontiers in Bioengineering and Biotechnology Chemical Engineering-Bioengineering
CiteScore
8.30
自引率
5.30%
发文量
2270
审稿时长
12 weeks
期刊介绍: The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs. In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书